Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.42)
# 2,486
Out of 4,959 analysts
166
Total ratings
44.79%
Success rate
-0.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $38.71 | +29.17% | 23 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $70 → $12 | $2.95 | +306.78% | 6 | Jul 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $52.82 | +62.82% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $2.74 | +118.98% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $5.66 | +165.02% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.87 | +109.06% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $3.22 | +86.34% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $12.68 | +57.79% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $5.06 | +77.87% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $2.17 | +176.50% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.91 | +360.36% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $6.76 | +195.86% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.32 | +1,187.88% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $6.28 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.88 | +354.55% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.41 | +515.84% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.44 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $2.78 | +115.83% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $171.46 | +63.30% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.57 | +88.09% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.13 | - | 10 | Jan 19, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $38.71
Upside: +29.17%
Jasper Therapeutics
Jul 8, 2025
Maintains: Market Outperform
Price Target: $70 → $12
Current: $2.95
Upside: +306.78%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $52.82
Upside: +62.82%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $2.74
Upside: +118.98%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.66
Upside: +165.02%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.87
Upside: +109.06%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.22
Upside: +86.34%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $12.68
Upside: +57.79%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.06
Upside: +77.87%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $2.17
Upside: +176.50%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.91
Upside: +360.36%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $6.76
Upside: +195.86%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.32
Upside: +1,187.88%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.28
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.88
Upside: +354.55%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.41
Upside: +515.84%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $2.78
Upside: +115.83%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $171.46
Upside: +63.30%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.57
Upside: +88.09%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.13
Upside: -